The earliest report of cell-free DNA in healthy individuals dates to the 1940s and
it has been most widely adopted in medicine in assessing fetal risk of chromosomal
abnormalities in pregnant women. In oncology, there are a variety of clinical applications
for a minimally invasive blood test for cell-free DNA released from tumor cells. The
increased adoption of targeted cancer therapies underscores the need to augment invasive
tissue biopsies with alternative detection methods that rapidly monitor treatment
response. In this lecture, I will review the clinical indications for cell-free DNA
testing and discuss opportunities and challenges of cell-free DNA test validation
in pregnancy and oncology.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cancer GeneticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
